What are the approved indications for Riflimab? Latest clinical scope of application

Retifanlimab, trade name Zynyz, is a new generation PD-1 (programmed death receptor-1) immune checkpoint inhibitor developed by Incyte. This drug activates T cell immune function by blocking the binding of PD-1 and its ligands PD-L1/PD-L2 to enhance the body's ability to clear tumor cells. It is one of the important representatives in the field of immuno-oncology treatment in recent years. Currently, Riflimab has been approved by the US FDA for the treatment of a variety of advanced malignant tumors, especially those with high immune evasion mechanisms.

First, it has been clearly approved for the treatment of metastatic or locally recurrent Merkel Cell Carcinoma (MCC), a rare but highly aggressive neuroendocrine skin cancer for which traditional therapies have limited effectiveness. PD-1 antibody drugs provide the possibility of more durable and deep remission.

Secondly, Riflimab is also used to treat Squamous Cell Carcinoma of the Anal Canal (SCAC), including two situations: first, in combination with carboplatin and paclitaxel, as a first-line treatment for patients with inoperable local recurrence or metastatic SCAC; second, as a single agent, for patients with disease progression or intolerance after previously receiving platinum-containing chemotherapy.

In addition, Riflimab is currently conducting multiple Phase III clinical studies involving other tumor types such as cervical cancer, lung cancer and head and neck squamous cell carcinoma. It is expected that its clinical application scope will be further expanded in the future. It is worth mentioning that Zynyz is a fixed-dose intravenous injection preparation that can be administered once every 4 weeks. It has good compliance and convenience of operation, and is especially suitable for patient groups with medium and long-term management. Although the drug has not yet been officially launched in mainland China, its international recognition is increasing. With the release of more real-world research results, its application prospects in Asia also deserve great attention.

Reference materials:https://www.drugs.com/mtm/retifanlimab.html